Allarity Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ALLR, updated each market day.
ALLR AI Sentiment
AI sees no strong directional signal for Allarity Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Sector
Exchange
Market Cap
$18,191,827
Cap Tier
Employees
8
Headquarters
BOSTON, MA
Listed Since
Dec. 21, 2021
Website
ALLR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALLR Volatility
Allarity Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
